- PENG
- HTFL
- CBLL
AI risk is suddenly front-page news. Financiers are warning that high valuations and concentrated exposure in <a href="https://myappsplus.com/virginia-governor-orders-new-cybersecurity-plan-to-address-artificial-intelligence-risks/" title="Virginia governor orders new cybersecurity plan to address artificial intelligence risks”>artificial intelligence could feed the next market downturn, yet the same technology is quietly reshaping how smaller specialists build tools in automation, data and machine learning. That disconnect is where opportunity often hides. This article highlights three under-the-radar AI-focused small caps that show how targeted exposure can complement a broader portfolio.
The three stocks below are just a small sample, and the full screen surfaced 35 more AI-focused small caps with equally compelling narratives that are not covered here. To identify potential retirement-level winners across early-stage machine learning, automation, and data intelligence, head straight to the AI Small Caps screener
CeriBell gives this AI Small Caps list a real-world medical anchor, using artificial intelligence to turn raw brainwave data into bedside decisions that matter for stroke and seizure patients.
CeriBell, a Sunnyvale based medtech business, sells the Ceribell System for point of care EEG in acute care, pairing portable hardware with its Clarity AI seizure detection software and a cloud EEG portal. It generated about $102 million from diagnostic kits and equipment, all in the United States, and has a market value of roughly $1.0 billion.
“Ongoing shift within hospitals to formal, guideline based seizure management protocols for stroke, cardiac arrest and hemorrhagic patients is driving broader, mandated EEG use, supporting higher utilization per account and an increasing mix of high margin recurring revenue.”
What happens if one quiet shift in how hospitals pay for this kind of AI monitoring pushes margins in a very different direction?
If that margin reset is even partly on the table, you will want the full narrative for CeriBell to see how reimbursement, competition and capital needs all intersect.
HeartFlow leans directly into the AI Small Caps theme by using artificial intelligence and physics based modeling to turn coronary CT scans into decision tools that cardiologists can act on at scale.
HeartFlow runs a single AI enabled coronary artery disease detection business that produced about US$212 million in revenue, and the stock carries a market value of roughly US$4.9b.
Instead of chasing broad AI hype, HeartFlow focuses on one clear problem: turning CT images into a richer, data heavy map of how blood actually moves through clogged arteries.
